Sat, Jul 26, 2014, 1:28 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Neuralstem, Inc. Message Board

mmbuddha 74 posts  |  Last Activity: 16 hours ago Member since: Aug 10, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    July investor presentation

    by editroid Jul 25, 2014 12:57 PM
    mmbuddha mmbuddha 16 hours ago Flag

    With all due respect, take a look at the Neuralstem Presentation dated February 7, 2014, slide page 18, which shows a slide as follows:

    "First-in-class Neurogenic Small Molecule Drugs – Reverse
    Hippocampal Atrophy

    War Fighter of the Future” DOD program, initial funding
    • Patented Novel Neurogenic Compounds
    • 100% owned for commercialization
    • Early mover advantage
    • NSI-189: Lead Compound
    • Recruit endogenous neural stem cells to generate more
    new neurons in adult brain
    • NSI-189 Lead drug candidate:
    • Increases hippocampal volume - + 20% in animal studies
    • Rebuilds hippocampus structurally
    • Enhances neurogenesis
    • Small Molecule Discovery and Development Enabled by Proprietary Stem Cell-based Screening

    Note the reference to War Fighter of the Future DOD program, initial funding. There are many other references by Garr on its initial grant that led to its discovery.

  • Reply to

    July investor presentation

    by editroid Jul 25, 2014 12:57 PM
    mmbuddha mmbuddha 22 hours ago Flag

    "...given that the drug was developed with funding from the Department of Defense specifically to treat veterans suffering from it." Actually, I believe it was funding from the DOD to produce the "super soldier," that could function longer and stronger, but I understand PTSD may be an indication worth pursuing.

  • Reply to

    Wow, The Board Has Become Quiet

    by billistheman2000 Jul 24, 2014 12:40 PM
    mmbuddha mmbuddha Jul 24, 2014 1:01 PM Flag

    5) BTD and/or AA filing for NSI-566 for ALS;
    6) Submission of NSI-189 Phase I Clinical Report by Fava;
    7) Commencement of Phase II NSI-189 for MDD and/or Alzheimer's; and,
    8) Possible collaboration/Partnership for NSI-189.

  • mmbuddha mmbuddha Jul 22, 2014 12:27 PM Flag

    While I may agree with your prediction of 18-20 upon approval, I cannot believe Baupost is in this for approval only of + or - $20/share. I will be following closely big players like Baupost to see if/when/how much they unload to determine an exit. GLTU,

  • Reply to

    What happens if this breaks 2.96?

    by peteharmisan Jul 8, 2014 6:49 PM
    mmbuddha mmbuddha Jul 8, 2014 8:04 PM Flag

    Ok, Mr. Wizard, what happens when CUR releases Phase II ALS data? While you are at it, what happens when stroke results are released from the Beijing stroke trial? And after that, what happens when CUR releases start of NSI-189 for MDD and Alzheimer's?

  • Reply to

    What happens if this breaks 2.96?

    by peteharmisan Jul 8, 2014 6:49 PM
    mmbuddha mmbuddha Jul 8, 2014 7:36 PM Flag

    Before I answer your question, does the filing of BTD come before the issuance of any shares?

  • Reply to

    What happens if this breaks 2.96?

    by peteharmisan Jul 8, 2014 6:49 PM
    mmbuddha mmbuddha Jul 8, 2014 6:51 PM Flag

    What happens when CUR files for BTD for NSI-566 for ALS??

  • http://blogs.marketwatch.com/health-exchange/2014/07/08/tests-may-identify-vulnerability-to-alzheimer-disease-in-elderly-patients/

  • Reply to

    S3 - Discussion

    by tliuall Jul 2, 2014 11:06 AM
    mmbuddha mmbuddha Jul 3, 2014 1:06 PM Flag

    Thanks. Not sure I agree that any of those arguments is a strong logical one. Making an acquisition using a part or all of the 150 million shares can be undone by the acquiring company by then selling the acquired company that CUR would make presumably at the same or similar price CUR acquired it (if it had any economic merit); and, having 150 MM additional shares authorized is a little overkill to prudently finance additional clinical trials that are anticipated, imo. Not trying to be a killjoy, but wanting to truly understand the arguments. Not sure I still do understand the argument as a preemptive strike to CUR being bought at a hostile takeover. Why not simply seek a shareholder vote on an amendment to the Articles establishing a "poison pill" provision or two if that were the goal?

  • Reply to

    S3 - Discussion

    by tliuall Jul 2, 2014 11:06 AM
    mmbuddha mmbuddha Jul 3, 2014 10:26 AM Flag

    I am not sure I understand how authorizing 150 MM more shares can be used to "fight any hostile attempts to take them over and to have more leverage in discussions with Big Pharm..." Can you spell that logic out more for me? Serious question, I just do not follow that logic.

  • Reply to

    S3 - Discussion

    by tliuall Jul 2, 2014 11:06 AM
    mmbuddha mmbuddha Jul 3, 2014 9:03 AM Flag

    I am not sure I follow that logic. Can you explain it to me?

  • Reply to

    Spinal cord injury trial in the USA

    by joeycav11 Jul 1, 2014 5:38 PM
    mmbuddha mmbuddha Jul 1, 2014 6:41 PM Flag

    From what I can see with the previous market's reactions to CUR news, as remarkable as they may seem, that should drive the price down 50 cents...

  • Reply to

    Garr's comments on a partner for NSI-189

    by techtrader79 Jul 1, 2014 3:15 PM
    mmbuddha mmbuddha Jul 1, 2014 5:01 PM Flag

    Bill:

    What you say may very well be true with NSI-189 being more than just another depression drug, but I still say that phase II results would exponentially strengthen CUR's position to negotiate better terms than they could get now. It is worth the risk in waiting, imo. This is not CUR's only iron in the fire. CUR has NSI-566 for what appears to be many indications as well. Partnering now I think takes some risk off the table for CUR, but I think it would be at too high a cost in lost royalties, etc... especially when you consider the paradigm shifting potential of NSI-189. Of course, the devil of a partnership deal now would all be in the details. As a long term shareholder, I would still be willing to wait til Phase II results to consider partnering, especially given the "remarkable" results of Phase 1B.

  • Reply to

    Garr's comments on a partner for NSI-189

    by techtrader79 Jul 1, 2014 3:15 PM
    mmbuddha mmbuddha Jul 1, 2014 3:45 PM Flag

    If they are talking, I think they are agreeing to parameters for discussion after Phase II results. For example, CUR might say that it is more inclined to give up on upfront payments to increase royalties and milestone payments. This may be the case since NSI-566 may be much closer to commercialization if granted BTD than NSI-189. Of course the specific numbers will have to wait until the Phase II results are known. But certainly talking and exchanging expectations at this point is not out of the question, imo.

  • Reply to

    Garr's comments on a partner for NSI-189

    by techtrader79 Jul 1, 2014 3:15 PM
    mmbuddha mmbuddha Jul 1, 2014 3:30 PM Flag

    Partnering now before Phase II results in NSI-189 would be premature and short-change shareholders, UNLESS, of course, CUR is made an offer it simply cannot refuse. I see no reflected value of NSI-189 on Market Cap today. I am happy if CUR GIA through Phase II and does not partner with anyone. Any partner after Phase II will have to pay much more (upfront payment, milestone payments and/or retained royalties by CUR).

  • Reply to

    Zack's (Under)Valuations

    by tonycoder Jun 28, 2014 10:25 AM
    mmbuddha mmbuddha Jun 28, 2014 11:51 AM Flag

    I understand what you are saying JB, and it must be true given the SP today, BUT, I believe the market has deeply discounted NSI-189 to a point where the market is basically putting no value to it, even though the Phase IB results were "remarkable," as described by its CEO, and especially given its decision to GIA thru Phase II results. The market is giving virtually no value to NSI-189 today, but that will change as we get closer to the initiation of Phase II trials, imo, and on possible multiple indications (MDD and Alzheimer's, if not others). In the interim, SP will adjust based upon ALS Phase II results, possible BTD filing and designation, and/or RTT treatment in those states where it is allowed. Throw in the Stroke trial results that will be accelerating from Beijing, and the SCI phase I trials that will begin some time this year, and you wonder how anyone can be short with all these irons in the fire?

  • Reply to

    Article submitted thread erased

    by jbkenser Jun 26, 2014 4:24 PM
    mmbuddha mmbuddha Jun 26, 2014 11:15 PM Flag

    OK, I agree with that now. Thanks for your analysis.

  • Reply to

    Article submitted thread erased

    by jbkenser Jun 26, 2014 4:24 PM
    mmbuddha mmbuddha Jun 26, 2014 7:27 PM Flag

    I have the same question. Retention of 10% royalties after Phase II seems awfully low, imo.

  • Reply to

    Old time investors

    by whatchutalkingbout Jun 25, 2014 5:46 PM
    mmbuddha mmbuddha Jun 26, 2014 9:06 AM Flag

    Just checked my account. I started purchasing in March of 2008, and have not sold 1 share since. The CUR storyline (in proving its science) has just kept getting better. I have gone to every annual shareholder meeting since, but not this year since it is in CA. Looking forward to comments from those that will be there.

  • Reply to

    With the PR

    by kylekneale Jun 18, 2014 9:31 AM
    mmbuddha mmbuddha Jun 18, 2014 9:38 AM Flag

    I agree. Very positive data, and positive comments regarding future trials.

CUR
3.20-0.05(-1.54%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.